The Supervisory Board of Fresenius Medical (FMS) Care appointed Joseph Turk as a member of the Management Board, effective January 1, 2026. Mr. Turk will serve as CEO of the global operating segment Care Enablement. Turk will succeed Dr. Katarzyna Mazur-Hofsass as part of a planned transition after she informed the Supervisory Board of her intention to retire. Dr. Mazur-Hofsass joined Fresenius Medical Care in 2018 and has been leading Care Enablement since its creation in 2022. Turk joined Fresenius Medical Care in 2019, following the acquisition of NxStage Medical. He currently serves as Executive Vice President of Global Home and Critical Care Therapies as well as Head of US Commercial Operations.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Cautious Hold Rating for Fresenius Medical Care Amidst Stagnant Growth and Uncertain Recovery
- Fresenius Medical Care Boosts Value-Based Care with Strategic Investment and Leadership Change
- Fresenius Medical downgraded to Sell from Neutral at UBS
- Fresenius Medical price target raised to EUR 46 from EUR 43 at Morgan Stanley
- Fresenius Medical Care Launches EUR 1 Billion Share Buyback Program